Definitive concurrent chemoradiotherapy in a patient with stage IV non-small cell lung cancer due to cervical lymph node metastases

• Published in: International cancer conference journal Vol. 7; no. 4; pp. 131 - 133
• Main Authors: Takahashi, Shigeo, Tarumi, Shintaro, Nakano, Jun, Fujiwara, Atsushi, Anada, Masahide, Kinoshita, Toshifumi, Go, Tetsuhiko, Yokomise, Hiroyasu, Shibata, Toru
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.10.2018; Springer Nature B.V
• Subjects: Adenocarcinoma; Anemia; Anorexia; Cancer therapies; Carboplatin; Case Report; Chemoradiotherapy; Chemotherapy; Clinical medicine; Cytotoxicity; Dermatitis; Ethics; Kinases; Lung cancer; Lymph nodes; Lymphatic system; Medical prognosis; Medicine; Medicine & Public Health; Metastases; Metastasis; Mutation; Neutropenia; Non-small cell lung carcinoma; Oncology; Patients; Radiation therapy; Small cell lung carcinoma; Surgical Oncology; Thrombocytopenia; Lung carcinoma; Advanced; Radical; Concomitant; Chemoradiation
• ISSN: 2192-3183; 2192-3183
• DOI: 10.1007/s13691-018-0335-0

In the American Society of Clinical Oncology guideline, it is mentioned that systemic therapy is a standard treatment, but there is no cure for patients with stage IV non-small cell lung cancer (NSCLC). Recent technical advances have facilitated the delivery of curative-intent radiation doses to some stage IV patients. In this report, we introduce a long-term disease-free survivor after concurrent chemoradiotherapy (CRT) and discuss considerations for this treatment. The patient was a 61-year-old woman diagnosed with stage IV adenocarcinoma of the lung classified as cT4N3M1c; the M1c classification was because of multiple synchronous pathologically proven cervical lymph node metastases (CLNM). We administered concurrent CRT to all lesions with a dose of 60 Gy in 30 fractions over 6 weeks. Concurrent chemotherapy consisted of two cycles of carboplatin and pemetrexed. Adjuvant chemotherapy was performed with five cycles of carboplatin and pemetrexed followed by three cycles of pemetrexed alone. As of 43 months after CRT, the patient was still alive without disease. In conclusion, our patient with stage IV NSCLC due to CLNM achieved long-term disease-free survival by concurrent CRT as with patients with locally advanced NSCLC. Patient subgroups should be explored to achieve long-term disease-free survival after definitive CRT in patients with stage IV NSCLC due to CLNM.